Author:
Zhang Chang,Tsang Yuen,He Jinghua,Panjabi Sumeet
Funder
Janssen Business Technology Commercial Data Sciences
Janssen Scientific Affairs
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference28 articles.
1. Badlam JB, Bull TM. Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. Ther Adv Chronic Dis. 2017;8(2–3):47–64.
2. Bergot E, De Leotoing L, Bendjenana H, et al. Hospital burden of pulmonary arterial hypertension in France. PLoS ONE. 2019;14(9): e0221211.
3. Burger CD, Long PK, Shah MR, et al. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014;146(5):1263–73.
4. Burke JP, Hunsche E, Régulier E, Nagao M, Buzinec P, Drake W III. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. Am J Manag Care. 2015;21(3 Suppl):s47-58.
5. Kirson NY, Birnbaum GH, Ivanova JI, Waldman T, Joish V, Williamson T. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Appl Health Econ Health Policy. 2011;9(5):293–303.